Neurology is considered a cognitive field, with thoughtful practitioners who are driven by empiric data. With the development of guidelines, practice parameters, and now a review of how physicians practice, this notion could be called into question.
There is no doubt that evidence-based medicine (EBM) should be and is the basis for the practice of modern medicine. Medical school curricula worldwide have recognized the importance of EBM, incorporating it into standard medical student education. The American Academy of Neurology (AAN), recognizing the need to supplement this type of thinking, developed a resident education program covering the basics of EBM. 1 So how do we as neurologists fare in the practice of EBM? Our track record is mixed.
We hear our colleagues utter, "there is no evidence to support that." That statement is more an editorial comment than a valid conclusion. EBM is built on the principle that there exists a hierarchy of evidence, some of which is strong and other weak, with the rest falling somewhere in between. Data, properly collected, should not be considered valid or invalid, but rather strong or weak. Similarly, an individual's opinion should not be thought of as valid or invalid but rather as a type of evidence, albeit weak.
An example can be found in fosphenytoin: when introduced, there was much controversy about its use, not based on evidence but rather on its cost. Many thought it was superior to phenytoin, on a safety basis, although with similar efficacy. Many advocated its use in seizure emergencies. An article described a protocol for its use in nonemergency situations, 2 developed through a consensus process involving epilepsy experts and those who treated seizures. Some of the independent reviewers robustly criticized the article because "it was not data driven." In an accompanying editorial, 3 it was argued that in the absence of doubleblind, placebo-controlled studies, we sometimes have to accept experience of clinicians as one level of evidence to support our practices.
The AAN utilizes a well-structured model, classifying studies using a ranking system and translating these into recommendations (tables 1 and 2). 4 It also has a well-developed process for developing evidence-based guidelines and reviews. There are now multiple guidelines for the use of antiepileptic medications. [5] [6] [7] Both the AAN and the International League Against Epilepsy have identified that phenytoin and carbamazepine have the highest level of evidence for the treatment of partial onset seizures, with or without secondary generalization. Yet expert consensus, a proxy for real practice, showed that carbamazepine and oxcarbazepine were the first choices for monotherapy, along with lamotrigine and levetiracetam. 8 The problem with this practice, from an evidence standpoint, is that both oxcarbazepine and lamotrigine have only class C evidence supporting their use in this setting while levetiracetam is not rated. Phenytoin, which has class A evidence to support its use, is not among the consensus choices for treatment. It could be argued that the problem lies, in part, with the guidelines themselves, which are of necessity narrowly focused on particular issues. Some guidelines are Another AAN guideline for temporal lobectomy in the treatment of epilepsy, along with a welldesigned clinical trial, 9, 10 does not suffer from these criticisms. The evidence is so clear that the presence of this information in highly regarded, and well-read, journals should change behavior. Englot and colleagues, 11 in this issue of Neurology ® , look at the trends for epilepsy surgery in the United States over the past 20 years, a time when the AAN guideline became public as did the results of the clinical trial for surgery. While one must always be careful when interpreting data from a database (in this case the Nationwide Inpatient Sample hospital discharge database), the data from this study are compelling and tell a somewhat troubling story. Despite an increase in hospitalizations over time for an epilepsy diagnosis, there was no increase in overall surgical rates. In fact, while the total number of hospitals in which surgical epilepsy services increased, the number of procedures decreased. Further, surgery rates were lower in minority patients as well as those insured by Medicaid or Medicare. These trends did not change over the time in this study. There are many reasons that could explain these findings: more antiseizure medications, leading to longer trials and combination of trials of medication; and vagus nerve stimulation, which also became available during the study period. These treatments might delay surgical intervention. Given the widely disseminated data that medically refractoriness can be defined early in the course of medical treatment for epilepsy, 12 the delay or reduction in epilepsy surgery is hard to understand or defend.
So the question posed in the title remains, are neurologists data driven? At best, the evidence appears weak, at least in regard to epilepsy treatments and appropriate referral for surgical intervention. We can, and should, do better. 
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